Keratoconjunctivitis after cataract surgery and protective effect of rebamipide ocular solution.

Keratoconjunctivitis after cataract surgery and protective effect of rebamipide ocular solution. - Post operative keratoconjunctivitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026310

Enrollment

Registered

2017-06-30

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Interventions

Patients received 0.1% diclofenac ocular solution without preservative three times daily one day after the surgery and continuedfor 28 days. Patients received 0.1% diclofenac ocular solution without

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients underwent cataract surgery.

Exclusion criteria

Exclusion criteria: Patients with diabetes mellitus, dry eye, glaucoma, history of glaucoma.

Design outcomes

Primary

Measure	Time frame
Evaluation of goblet cell density of conjunctiva 1 month after the surgeries.	—

Secondary

Measure	Time frame
Evaluation of BUT, anterior chamber inflammation and ocular surface disease index (OSDI) on 1 month and 2 month after the surgeries.	—

Countries

Japan

Contacts

Public ContactHisashi Matsubara

Mie University Department of Ophthalomology

hmatsu@clin.medic.mie-u.ac.jp059-231-5027

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026